Novartis India

Why is Novartis India Ltd falling/rising?

As of 09-Aug, Novartis India Ltd's stock price is rising to 1,609.90, driven by strong financial performance, a year-to-date increase of 106.66%, and positive investor sentiment, including increased institutional participation. The company's net-debt-free status and robust growth metrics further support this bullish trend.

As of 09-Aug, Novartis India Ltd's stock price is rising, currently at 1,609.90, reflecting a change of 6.35 (0.4%) upwards. This upward movement can be attributed to several factors. Firstly, the stock has demonstrated strong performance over various periods, with a year-to-date increase of 106.66%, significantly outperforming the benchmark Sensex, which has declined by 7.89% during the same timeframe. Additionally, the stock has shown a robust return of 72.22% over the past year, again surpassing the Sensex's decline of 2.63%.<BR><BR>Moreover, the company is net-debt free and has reported healthy long-term growth, with an operating profit growth rate of 40.23%. Recent positive results declared in June 2026, following two consecutive negative quarters, have also contributed to investor confidence. The company reported its highest cash and cash equivalents at Rs 667.70 crore and a strong debtors turnover ratio of 9.56 times, alongside net sales reaching Rs 103.81 crore.<BR><BR>Furthermore, there has been increasing participation from institutional investors, who have raised their stake by 0.81% in the last quarter, indicating a positive outlook from more sophisticated investors. The stock's performance today is inline with the sector, and despite opening with a loss, it has recovered and is trading above its moving averages across various timeframes, suggesting a bullish trend.<BR><BR>In summary, the combination of strong financial performance, positive investor sentiment, and institutional interest has led to the rise in Novartis India Ltd's stock price.

Which are the latest news on Novartis India?

Are Novartis India Ltd latest results good or bad?

Novartis India Ltd's latest Q1 FY27 results are strong, with a net profit of ₹32.21 crores, up 27.56% quarter-on-quarter and 16.62% year-on-year, alongside revenue growth of 14.64% sequentially. The operating margin improved to 33.63%, indicating enhanced operational efficiency and a positive outlook for the company.

Novartis India Ltd's latest results for Q1 FY27 are quite strong, indicating a positive performance overall. The company reported a net profit of ₹32.21 crores, which reflects a significant increase of 27.56% quarter-on-quarter and 16.62% year-on-year. Revenue also saw a robust growth, reaching ₹103.81 crores, up 14.64% sequentially and 18.57% compared to the same quarter last year.<BR><BR>Additionally, the operating margin improved dramatically to 33.63%, marking an increase of 1,086 basis points from the previous quarter, which is the highest recorded in at least seven quarters. This margin expansion is a strong indicator of improved operational efficiency and a favorable product mix.<BR><BR>Overall, the results suggest that Novartis India is experiencing strong operational momentum, with significant improvements in both profitability and revenue growth, positioning the company well within the pharmaceuticals sector.

Should I buy, sell or hold Novartis India Ltd?

When is the next results date for Novartis India Ltd?

The next results date for Novartis India Ltd is July 23, 2026.

The next results date for Novartis India Ltd is scheduled for July 23, 2026.

How big is Novartis India?

As of 10th June, Novartis India Ltd has a market capitalization of 3,253.00 Cr, categorized as Small Cap, with recent net sales of 354.33 Cr and net profit of 93.18 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Novartis India Ltd has a market capitalization of 3,253.00 Cr, categorized as Small Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 354.33 Cr, while the sum of Net Profit for the same period is 93.18 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is for March 2025, with Shareholder's Funds amounting to 784.96 Cr and Total Assets valued at 932.33 Cr.

Who are in the management team of Novartis India?

The management team of Novartis India includes C Snook (Chairman), Sanjay Murdeshwar (Vice Chairman & Managing Director), Shilpa Joshi (CFO), and several independent directors. They are responsible for guiding the company's strategy and ensuring regulatory compliance.

The management team of Novartis India includes the following key members:<BR><BR>- **C Snook**: Chairman (Non-Executive)<BR>- **Jai Hiremath**: Independent Director<BR>- **Sandra Martryes**: Independent Director<BR>- **Sanjay Murdeshwar**: Vice Chairman & Managing Director<BR>- **Sanker Parameswaran**: Independent Director<BR>- **Nikhil Malpani**: Company Secretary & Compliance Officer<BR>- **Shilpa Joshi**: Whole Time Director & Chief Financial Officer<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulations.

Who are the peers of the Novartis India?

Novartis India's peers include RPG LifeScience, Gufic BioScience, SMS Pharma, Unichem Labs, Aarti Drugs, Panacea Biotec, Solara Active, Dishman Carbogen, and Morepen Labs. In terms of performance, Novartis India has a 1-year return of 29.32%, higher than Dishman Carbogen but lower than SMS Pharma's 49.20%.

Peers: The peers of Novartis India are RPG LifeScience, Gufic BioScience, SMS Pharma, Unichem Labs, Aarti Drugs, Panacea Biotec, Solara Active, Dishman Carbogen, and Morepen Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at RPG LifeScience and Novartis India, while Average management risk is found at Gufic BioScience, SMS Pharma, Aarti Drugs, and Morepen Labs, and the rest. Growth is rated as Good at Unichem Labs and Novartis India, while Below Average growth is seen at RPG LifeScience, Gufic BioScience, SMS Pharma, Aarti Drugs, Panacea Biotec, Solara Active, Dishman Carbogen, and Morepen Labs. In terms of Capital Structure, Excellent is noted for RPG LifeScience and Novartis India, Good for Unichem Labs and Aarti Drugs, and Average for Gufic BioScience and SMS Pharma, while Below Average is found at Panacea Biotec, Solara Active, Dishman Carbogen, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is SMS Pharma at 49.20%, while Dishman Carbogen has the lowest at -38.27%. Novartis India's 1-year return of 29.32% is higher than that of Dishman Carbogen but lower than that of SMS Pharma. Additionally, Dishman Carbogen and Panacea Biotec have negative six-month returns.

What does Novartis India do?

Novartis India Ltd, a subsidiary of Swiss pharmaceutical company Novartis, manufactures and markets drugs in the Pharmaceuticals & Biotechnology industry. As of March 2026, it reported net sales of 91 Cr and a net profit of 25 Cr, with a market cap of INR 3,253 Cr.

Overview:<BR>Novartis India Ltd is engaged in the manufacturing and marketing of drugs and pharmaceutical products, operating within the Pharmaceuticals & Biotechnology industry and classified as a Small Cap company.<BR><BR>History:<BR>Incorporated on 13 December 1947, Novartis India Ltd is a subsidiary of the Swiss pharmaceutical giant Novartis. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 91 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 25 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 3,253 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 35.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 1.91% <BR>Debt-Equity: -0.81 <BR>Return on Equity: 11.39% <BR>Price to Book: 3.96 <BR><BR>Contact Details:<BR>Address: The Inspire BKC Part 601 & 701, Bandra Kurla Complex Bandra(E) Mumbai Maharashtra : 400051 <BR>Tel: 91-022-50243000 <BR>Email: india.investors@novartis.com <BR>Website: http://www.novartis.in

Is Novartis India overvalued or undervalued?

As of November 4, 2025, Novartis India is fairly valued with a PE ratio of 19.90, making it a more attractive investment compared to peers like Sun Pharma and Divi's Lab, despite its recent underperformance against the Sensex.

As of 4 November 2025, Novartis India's valuation grade has moved from expensive to fair, indicating a shift in its market perception. The company is currently fairly valued, with a PE ratio of 19.90, a Price to Book Value of 0.27, and a PEG ratio of 0.91. These ratios suggest that the stock is reasonably priced compared to its earnings growth potential.<BR><BR>In comparison to its peers, Novartis India stands out with a more favorable valuation than Sun Pharma, which has a PE ratio of 35.41, and Divi's Lab, which has a PE ratio of 78.59. Other peers like Dr. Reddy's Labs and Cipla are also attractive but at higher valuations of 17.36 and 22.35, respectively. While Novartis India has underperformed the Sensex over the past year with a return of -19.75% compared to the Sensex's 5.94%, its current valuation metrics suggest it may be a more appealing investment opportunity relative to its peers.

How has been the historical performance of Novartis India?

Novartis India has experienced fluctuating financial performance, with net sales declining from INR 490.68 crore in March 2019 to INR 356.27 crore in March 2025, while operating profit significantly improved from INR 12.28 crore to INR 133.38 crore during the same period, indicating a recovery in profitability despite declining sales. Total assets and liabilities also decreased, reflecting reduced financial obligations.

Answer:<BR>The historical performance of Novartis India shows fluctuations in key financial metrics over the years, with notable trends in net sales, operating profit, and profit after tax.<BR><BR>Breakdown:<BR>Novartis India's net sales have seen a decline from INR 490.68 crore in March 2019 to INR 356.27 crore in March 2025, with a peak of INR 399.87 crore in March 2022. Total operating income followed a similar trend, decreasing from INR 490.68 crore in March 2019 to INR 356.27 crore in March 2025. Operating profit (PBDIT) has improved significantly, rising from INR 12.28 crore in March 2019 to INR 133.38 crore in March 2025, indicating a strong recovery in profitability. Profit before tax also increased from INR 85.77 crore in March 2019 to INR 130.42 crore in March 2025, while profit after tax showed a recovery from a loss of INR 3.72 crore in March 2022 to INR 100.90 crore in March 2025. The company's cash flow from operating activities improved from a negative INR 69 crore in March 2021 to INR 74 crore in March 2025, reflecting better operational efficiency. Total assets decreased from INR 1,052.90 crore in March 2020 to INR 932.33 crore in March 2025, while total liabilities also decreased from INR 1,052.90 crore in March 2020 to INR 932.33 crore in March 2025, indicating a reduction in financial obligations. Overall, Novartis India has shown a recovery in profitability and operational cash flow despite declining sales and total assets.

Is Novartis India technically bullish or bearish?

As of October 24, 2025, Novartis India is in a bearish trend with strong indications of weakness across multiple technical indicators, including the MACD, Bollinger Bands, and moving averages, showing no immediate signs of reversal.

As of 24 October 2025, the technical trend for Novartis India has changed from mildly bearish to bearish. The current stance is bearish with a strong indication of weakness. The weekly MACD is bearish, and both the weekly and monthly Bollinger Bands confirm a bearish outlook. Daily moving averages also indicate bearish momentum. The KST is bearish on both weekly and monthly time frames, while the Dow Theory shows no trend on the weekly but is mildly bearish on the monthly. Overall, the indicators suggest a continued bearish trend with no immediate signs of reversal.

Who are the top shareholders of the Novartis India?

The top shareholder of Novartis India is Novartis AG, holding 70.68% of the shares, followed by Atul Limited with 1.52%, and individual investors who own 23.11%. Additionally, foreign institutional investors hold 0.19%, while mutual funds have negligible holdings.

The top shareholders of Novartis India include Novartis AG, which holds the largest stake at 70.68%. Other notable shareholders include Atul Limited, with a holding of 1.52%, and individual investors who collectively own 23.11% of the shares. Additionally, there are 17 foreign institutional investors (FIIs) holding a small portion of 0.19%, and mutual funds are represented by six schemes, although they hold 0.0%.

Has Novartis India declared dividend?

Yes, Novartis India Ltd has declared a 500% dividend, amounting to ₹25 per share, with an ex-date of July 23, 2024. The dividend yield is 2.5%, and while recent returns have shown some volatility, the company has demonstrated strong long-term growth and returns.

Novartis India Ltd has declared a 500% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 500%<BR>- Amount per share: 25<BR>- Ex-date: 23 Jul 24<BR><BR>Dividend Yield: 2.5%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Novartis India experienced a price return of -2.95%, with no dividend return, resulting in a total return of -2.95%.<BR><BR>Over the past year, the company had a price return of -0.8% and a dividend return of 2.33%, leading to a total return of 1.53%.<BR><BR>In the 2-year period, the price return was 36.87%, with a dividend return of 4.26%, culminating in a total return of 41.13%.<BR><BR>For the 3-year period, the price return stood at 69.86% and the dividend return at 7.48%, resulting in a total return of 77.34%.<BR><BR>In the last 4 years, Novartis India recorded a price return of 53.94% and a dividend return of 6.34%, yielding a total return of 60.28%.<BR><BR>Lastly, over the 5-year span, the company achieved a price return of 64.44% and a dividend return of 11.55%, which resulted in a total return of 75.99%.<BR><BR>Overall, Novartis India has declared a significant dividend, and while recent returns have shown some volatility, the longer-term performance reflects strong growth and returns, particularly from dividends.